Thus, administration of transfer factor transfers the high responder phenotype to low responder recipients.

Dialysates from high responder strains contained transfer factor that would transfer delayed hypersensitivity to both high and low responder recipients.

The percentage of cholesterol absorption was significantly higher in untreated high responders than in other groups.

These studies suggest that ezetimibe decreases plasma cholesterol levels in high responders mainly by decreasing cholesterol absorption and increasing biliary cholesterol concentrations.